Sunday, February 15, 2026 2/15/2026

Articular Cartilage Tissue Engineering with Human Pluripotent Stem Cells

Award Number: R01AR077045
ORGANIZATION: NATIONAL INSTITUTE OF ARTHRITIS & MUSCULOSKELETAL & SKIN DISEASES
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)
PERIOD OF PERFORMANCE START DATE: 04/01/2021
PERIOD OF PERFORMANCE END DATE: 03/31/2027

Group Awards By:

View Award Description

Articular Cartilage Tissue Engineering with Human Pluripotent Stem Cells - ABSTRACT Impairment of articular cartilage function after injury and disease like osteoarthritis (OA), remains a major health problem. One of the major drawbacks of tissue engineering-based therapies for damaged joint articular cartilage is that the cartilaginous repair tissue formed by implanted mesenchymal stromal cells or endogenous progenitors does not resemble articular cartilage, likely due to fibrochondrogenesis and the endochondral ossification process. Joint cartilage is generated during embryogenesis by specialized GDF5+ cells called ‘interzone’ cells or ‘joint progenitors’. They are distinct from progenitors that give rise to growth plate chondrocytes. In this proposal, we aim to define the molecular targets that control articular-like permanent chondrocyte formation versus growth plate-like transient chondrocyte formation, by using novel GDF5+ mesenchymal cells developed from human pluripotent stem cells (hPSCs). During in vitro chondrogenesis, such cells express signs of primitive (or embryonic) articular chondrocytes but not of chondrocyte hypertrophy. Significantly, after transplantation of the cartilage they develop, no mineralization was observed for 8 weeks (i.e., permanent cartilage). Therefore, the hPSC-derived GDF5+ cells may share the activity of joint progenitors, although genome-wide RNA-sequencing (seq) analyses suggested association with developing tenocytes or ligamentocytes. In contrast, alternative hPSC-derived chondroprogenitors, SOX9+ cells, generated cartilage that readily underwent complete mineralization, mimicking growth-plate chondroprogenitors. Interestingly, when mixed with GDF5+ cells, the SOX9+ cell-derived cartilage behaved as permanent cartilage in a GDF5+ cell-dose-dependent manner, suggesting the involvement of a non-cell autonomous mechanism. Therefore, we first propose to test if the GDF5+ cells have a joint progenitor-like activity, characterize the (permanent) cartilage developed from them, and shed lights on how the cells generate permanent cartilage (Aim 1). Second, we plan to identify genes potentially involved in permanent cartilage formation from GDF5+ cells through comparative RNA-seq analyses of cartilage pellets developed from the GDF5+ and SOX9+ cells (Aim 2). We will then functionally validate the candidate genes (and their encoded proteins, inhibitors and activators if commercially available) for their ability to enable SOX9+ cells to generate articular-like permanent chondrocytes using gene knockout and overexpression techniques (Aim 3). We will then examine whether GDF5+ cells and such gene-modified SOX9+ cells induce more sustained repair of damaged joint cartilage than SOX9+ cells (Aim 4). Lastly, any of the genes defined in these studies will be manipulated similarly in therapeutically relevant adult mesenchymal stromal cells to confirm that targeting the same mechanisms will convert the adult stem cells to articular cartilage-forming cells (Aim 4). Thus, success of the proposed research will provide mechanistic insights into how articular-like permanent cartilage can be selectively formed from various chondrogenic cells, potentially leading to novel therapeutic strategies for effective, sustained repair of damaged cartilage.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2026 ( Subtotal = $0 )
2026	2025	STEADMAN PHILIPPON RESEARCH INSTITUTE	181 W MEADOW DR STE 1000	VAIL	CO	81657	EAGLE	USA	Arthritis, Musculoskeletal and Skin Diseases Research	000	5	2/10/2026	NON-COMPETING CONTINUATION	$0
														Subtotal = $0

Issue Date FY: 2025 ( Subtotal = $309,870 )
2025	2025	STEADMAN PHILIPPON RESEARCH INSTITUTE	181 W MEADOW DR STE 1000	VAIL	CO	81657	EAGLE	USA	Arthritis, Musculoskeletal and Skin Diseases Research	000	5	3/27/2025	NON-COMPETING CONTINUATION	$309,870
														Subtotal = $309,870

Issue Date FY: 2024 ( Subtotal = $333,971 )
2024	2024	STEADMAN PHILIPPON RESEARCH INSTITUTE	181 W MEADOW DR STE 1000	VAIL	CO	81657	EAGLE	USA	Arthritis, Musculoskeletal and Skin Diseases Research	000	4	3/29/2024	NON-COMPETING CONTINUATION	$309,870
2024	2024	STEADMAN PHILIPPON RESEARCH INSTITUTE	181 W MEADOW DR STE 1000	VAIL	CO	81657	EAGLE	USA	Arthritis, Musculoskeletal and Skin Diseases Research	001	4	6/7/2024	NON-COMPETING CONTINUATION	$24,101
														Subtotal = $333,971

Issue Date FY: 2023 ( Subtotal = $344,300 )
2023	2023	STEADMAN PHILIPPON RESEARCH INSTITUTE	181 WEST MEADOW DRIVE	VAIL	CO	81657	EAGLE	USA	Arthritis, Musculoskeletal and Skin Diseases Research	000	3	3/21/2023	NON-COMPETING CONTINUATION	$344,300
														Subtotal = $344,300

Issue Date FY: 2022 ( Subtotal = $340,857 )
2022	2022	STEADMAN PHILIPPON RESEARCH INSTITUTE	181 WEST MEADOW DRIVE	VAIL	CO	81657	EAGLE	USA	Arthritis, Musculoskeletal and Skin Diseases Research	001	2	5/6/2022	NON-COMPETING CONTINUATION	$30,987
2022	2022	STEADMAN PHILIPPON RESEARCH INSTITUTE	181 WEST MEADOW DRIVE	VAIL	CO	81657	EAGLE	USA	Arthritis, Musculoskeletal and Skin Diseases Research	000	2	3/8/2022	NON-COMPETING CONTINUATION	$309,870
														Subtotal = $340,857

Issue Date FY: 2021 ( Subtotal = $344,300 )
2021	2021	STEADMAN PHILIPPON RESEARCH INSTITUTE	181 WEST MEADOW DRIVE	VAIL	CO	81657	EAGLE	USA	Arthritis, Musculoskeletal and Skin Diseases Research	000	1	3/17/2021	NEW	$344,300
														Subtotal = $344,300

Grand Total All Awards = $1,673,298

Top

All Categories

About

Search

Reports

Data Submission

Award Information

Articular Cartilage Tissue Engineering with Human Pluripotent Stem Cells

Award Number: R01AR077045

ORGANIZATION: NATIONAL INSTITUTE OF ARTHRITIS & MUSCULOSKELETAL & SKIN DISEASES

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

PERIOD OF PERFORMANCE START DATE: 04/01/2021

PERIOD OF PERFORMANCE END DATE: 03/31/2027

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer